Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Celldex Therapeutics (CLDX) Income from Continuing Operations (2016 - 2025)

Celldex Therapeutics has reported Income from Continuing Operations over the past 16 years, most recently at 81317000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 81317000.0 for Q4 2025, down 72.68% from a year ago — trailing twelve months through Dec 2025 was 258757000.0 (down 63.91% YoY), and the annual figure for FY2025 was 258757000.0, down 63.91%.
  • Income from Continuing Operations for Q4 2025 was 81317000.0 at Celldex Therapeutics, down from 67044000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for CLDX hit a ceiling of 13373000.0 in Q2 2021 and a floor of 81317000.0 in Q4 2025.
  • Median Income from Continuing Operations over the past 5 years was 34325000.0 (2024), compared with a mean of 37045600.0.
  • Biggest five-year swings in Income from Continuing Operations: crashed 169.23% in 2022 and later grew 15.28% in 2023.
  • Celldex Therapeutics' Income from Continuing Operations stood at 20175000.0 in 2021, then plummeted by 31.29% to 26487000.0 in 2022, then tumbled by 63.5% to 43306000.0 in 2023, then fell by 8.74% to 47092000.0 in 2024, then plummeted by 72.68% to 81317000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 81317000.0 (Q4 2025), 67044000.0 (Q3 2025), and 56600000.0 (Q2 2025) per Business Quant data.